Evidence map›Paper›PMID 22140602›Full record

ArticleInternational journal of clinical and experimental medicine2011

An old herbal medicine with a potentially new therapeutic application in inflammatory bowel disease.

Richard Li, Philip Alex, Mei Ye, Ting Zhang, Ling Liu, Xuhang Li

Abstract read
In one paragraph

Article in International journal of clinical and experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 31 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Effects of Yunnan Baiyao on the Differentiation of HPDLFs on the Bio-OssInternational journal of general medicine · 2022
    Article
  5. RNA Sequencing Reveals the Regulation Mechanism of Yunnan Baiyao in Treating Skin Infection Caused byEvidence-based complementary and alternative medicine : eCAM · 2022
    Article
  6. Article
  7. Article
  8. Opening a Window on Attention: Adjuvant Therapies for Inflammatory Bowel Disease.Canadian journal of gastroenterology & hepatology · 2020
    Review
  9. Article
  10. GC/MS-Based Metabolomics Approach to Evaluate the Effect of Jackyakgamcho-Tang on Acute Colitis.Evidence-based complementary and alternative medicine : eCAM · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Paeoniflorin abrogates DSS-induced colitis via a TLR4-dependent pathway.American journal of physiology. Gastrointestinal and liver physiology · 2014
    Article
  18. Review
  19. Article
  20. Topical Yunnan Baiyao administration as an adjunctive therapy for bleeding complications in adolescents with advanced cancer.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2012
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Richard LiDivision of Gastroenterology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Philip Alex
Mei Ye
Ting Zhang
Ling Liu
Xuhang Li
Johns Hopkins University · USWuhan University · CN

Funding

Translational Research Enhancement CoreP30DK089502 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI ZACHOS, NICHOLAS CONSTANTINE · 2011 to 2020
$12.0M
Development of Biomarkers for IBD Using Protein ChipsR21DK077064 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI LI, XUHANG · 2007 to 2010
$515k
NIDDK NIH HHS P30 DK089502NIDDK NIH HHS R21 DK077064
6 · The paper itself

Abstract

Inflammatory Bowel Disease (IBD) is a chronic and frequently disabling inflammatory disorder of the intestine. New developments in IBD therapy are primarily focused on biologic treatments; however, they are both expensive and associated with significant side effects. Here, we provide the first preclinical evidence that YunNan BaiYao (YNBY), a well-known traditional Chinese herbal remedy frequently used for treating hemorrhages and wounds, can effectively alleviate experimental colitis. Oral administration of YNBY in drinking water significantly reduced the disease activities of both DSS- and TNBS-induced experimental colitis. Mechanistic studies revealed that the effectiveness of YNBY was not due to an anti-bacterial function since YNBY had no effect on E. coli growth. Rather, it exhibited an anti-inflammatory or immunosuppressive function: In the DSS colitis model, YNBY treatment decreased the levels of several pro-inflammatory cytokines in colonic mucosa, including TNFα, IL-12p40, and IL-17. Similar cytokine changes were also observed in mouse serum, suggesting that systemic changes in general reflect the changes in the affected colon. Significant down-regulation of IL-12p40 and IL-17, in addition to IFNγ, was also seen in TNBS-colitis model. Another potential mechanism for the anti-inflammatory effects of YNBY involves the selective suppression of pro-inflammatory immune cells: YNBY effectively suppressed the growth of multiple T- and B-lymphocytes, including Molt-4, Jurkat, and EBV-transformed human B-lymphocytes, more potently than 6-mecaptopurine (6-MP) and 5-aminosalicylic acid (5-ASA), two of the most commonly used first-line drugs in IBD therapy. In sharp contrast, YNBY exhibited no cytotoxicity to colonic epithelial cells (Caco-2 cells), even at the concentration 10-fold higher than that used in the lymphocyte model; and instead promoted cell spreading and wound healing. These results strongly suggest that YNBY not only has effective anti-inflammatory properties through suppressing lymphocyte growth and pro-inflammatory cytokine expression, but also can promote intestinal epithelial wound-healing and repair. Therefore, YNBY demonstrates strong potential as an alternative herbal therapy for IBD.

Indexed as

complementary and alternative medicine (CAM)Crohn's diseasecytokinesDSS-colitisherbal medicineIBDimmunesuppressionTNBS-colitiswound healingYunNan BaoYao (YNBY)

Identifiers

PMID22140602
PMCPMC3228586
OpenAlexW1569976050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.